Ruxolitinib in Estrogen Receptor Positive Breast Cancer

NCT01594216 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Estrogen-receptor Positive Invasive Metastatic Breast Cancer

Interventions

DRUG: Ruxolitinib
DRUG: Exemestane

Sponsor

Abramson Cancer Center at Penn Medicine